期刊
NATURE REVIEWS DRUG DISCOVERY
卷 12, 期 4, 页码 265-286出版社
NATURE PORTFOLIO
DOI: 10.1038/nrd3955
关键词
-
资金
- US National Institutes of Health [NIH/NS 041083-07]
- Cogan Foundation
- Jerry McDonald Huntington's Disease Research Fund
- US National Institutes of Health (NIH)
- US National Heart, Lung, and Blood Institute (NHLBI)
- US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-HL0921, R01-DK083385, R01-HL098294]
- Crohn's & Colitis Foundation of America (CCFA)
- Swedish Science Research Council [2553]
Adenosine signalling has long been a target for drug development, with adenosine itself or its derivatives being used clinically since the 1940s. In addition, methylxanthines such as caffeine have profound biological effects as antagonists at adenosine receptors. Moreover, drugs such as dipyridamole and methotrexate act by enhancing the activation of adenosine receptors. There is strong evidence that adenosine has a functional role in many diseases, and several pharmacological compounds specifically targeting individual adenosine receptors - either directly or indirectly - have now entered the clinic. However, only one adenosine receptor-specific agent - the adenosine A(2A) receptor agonist regadenoson (Lexiscan; Astellas Pharma) - has so far gained approval from the US Food and Drug Administration (FDA). Here, we focus on the biology of adenosine signalling to identify hurdles in the development of additional pharmacological compounds targeting adenosine receptors and discuss strategies to overcome these challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据